Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
about
Pneumococcal conjugate vaccines for preventing otitis mediaNasopharyngeal Bacterial Carriage in the Conjugate Vaccine Era with a Focus on PneumococciEfficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.Bronchiectasis in Children: Current Concepts in Immunology and MicrobiologyA reflection on invasive pneumococcal disease and pneumococcal conjugate vaccination coverage in children in Southern Europe (2009-2016)Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in south africa: a matched case-control study.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Randomized, open-label study of the impact of age on booster responses to the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in children in India.A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of PeruPneumococcal vaccination: what have we learnt so far and what can we expect in the future?A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and MaSerotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.Risk factors for death from invasive pneumococcal disease, Europe, 2010.Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese ChildrenImpact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children--a population-based study.Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the PhilippinesComment on: "Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children".Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.Risk factors for community-acquired pneumonia in children under five years of age in the post-pneumococcal conjugate vaccine era in Brazil: a case control studySafety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study.The Clinical Effectiveness of Pneumococcal Conjugate Vaccines: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Prevention of invasive pneumococcal diseases: beyond cultures.Decrease in antibiotic use, an added benefit of PCVsEffect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil.Issues in pediatric vaccine-preventable diseases in low- to middle-income countriesCost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2-4 years: A phase II randomized study.Conjugate pneumococcal vaccines: need and choice in India.Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland.Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trialCost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status.Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makersPreclinical evaluation of a chemically detoxified pneumolysin as pneumococcal vaccine antigen.Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children.Acute respiratory infections among under-5 children in India: A situational analysis.Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines.
P2860
Q24197520-E4D9325C-3299-4746-8D6B-FB2FFBE4A527Q26782298-023401B2-3743-4181-A222-0544E9E8FBBAQ33706016-357A50DB-37E7-4AC5-869A-923A5E0E7C56Q33734772-78BF2EA8-CEA4-4095-8B23-7CD0F9258D7AQ33848708-57A477EB-DCDA-4F6B-9F9A-91CED7B07FECQ34087769-66D63C18-571E-424D-82B2-728A6B986ED2Q34170021-9936C32D-5CCC-4524-9CFE-8CD0CE4BB33EQ34260771-75D1CA36-F197-445C-85E0-A6E7B326D961Q34291104-C6D14768-C38B-465E-8F03-F9098B3364EDQ34493821-284758B1-6354-4D3D-BFA7-3D709D069CBAQ34798448-DC0016C2-F289-464A-948C-8949D5E15A84Q34867264-5E9E27A2-06DE-4984-BCA5-3378A3BDA124Q35004396-004F97B0-0738-4A2E-A8D7-7187F08F14F2Q35130282-D0E22FCE-0BC9-42E3-AC99-3BC6681AECA1Q35186834-40C0AB39-8002-4B73-8389-78BF1DD79799Q35189319-E64814AA-BBEC-49C3-86AC-E6BEFA3EDBE1Q35679740-B11E1037-F2FF-458E-A925-69310DE6D234Q35752767-FCB49790-A6AB-4CA2-9DDE-0683BE99DEBEQ35867061-E96A4F66-82B4-4D16-9CA6-291C83E4C5A9Q35887689-58F0F1EB-2701-4D61-8223-D3118664DEE8Q36141815-6051C36E-FC87-49CA-9A80-D7570A8AF858Q36256464-728C7FC2-0181-48C7-902C-3FF74B87550FQ36294037-7D44F6B0-878E-4414-A893-C2BBC6C84AEAQ36713715-8D4C469B-01FC-428D-9139-74232020FB70Q36763202-C1A0A1FA-AFC6-4974-BDB1-E87002DCA3EAQ36798103-EE1E4347-99A0-4C9D-90AA-9C86D6202EF6Q36825163-CE795724-6AFF-400F-AB54-7816F4AE54DCQ37264972-F325FC9E-4D2D-4EC8-9E26-A66E54787017Q37309195-BE2BB88E-3020-46CC-8096-4CA059B09D57Q37309298-98C344F4-C555-4E4A-8FDA-D0FAB67CA8F2Q37318793-78EE072E-09DE-4A55-8BB2-91943A71C10EQ37445704-9FE00F26-4F14-4CCA-8A6A-2BDB54F5ED86Q37499448-8D722F31-02BF-4922-8351-9FE352F28C15Q37516888-A9FB6C85-531F-43C9-93D6-F55FBD4E483BQ37606399-FD90BF0E-81D3-4F5C-A7CA-B357848ADCEEQ37613616-72E4EB30-3165-42E5-AFC3-58097C0A5D8CQ37619137-2FDA7FF0-4032-4FC0-AAC9-F81544D2B430Q37621064-11EFD243-A84A-4A78-851F-25902E15D6F0Q37654302-919875AF-4DDA-4E37-972F-A4136B86F1F0Q37663184-28427FA2-3E80-4413-9A24-3FDC873C7EA4
P2860
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Effectiveness of the ten-valen ...... e: a cluster randomised trial.
@en
Effectiveness of the ten-valen ...... ae protein D conjugate vaccine
@nl
type
label
Effectiveness of the ten-valen ...... e: a cluster randomised trial.
@en
Effectiveness of the ten-valen ...... ae protein D conjugate vaccine
@nl
prefLabel
Effectiveness of the ten-valen ...... e: a cluster randomised trial.
@en
Effectiveness of the ten-valen ...... ae protein D conjugate vaccine
@nl
P2093
P1433
P1476
Effectiveness of the ten-valen ...... e: a cluster randomised trial.
@en
P2093
Arto A Palmu
Dorota Borys
Esa Ruokokoski
Heta Nieminen
Jukka Jokinen
Lode Schuerman
Lotta Siira
Marjan Hezareh
Marta Moreira
Patricia Lommel
P304
P356
10.1016/S0140-6736(12)61854-6
P407
P577
2012-11-16T00:00:00Z